(NASDAQ: PSTX) Poseida Therapeutics's forecast annual revenue growth rate of -15.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Poseida Therapeutics's revenue in 2024 is $82,502,000.On average, 2 Wall Street analysts forecast PSTX's revenue for 2024 to be $6,090,879,573, with the lowest PSTX revenue forecast at $5,817,459,000, and the highest PSTX revenue forecast at $6,364,300,146. On average, 2 Wall Street analysts forecast PSTX's revenue for 2025 to be $2,181,547,125, with the lowest PSTX revenue forecast at $969,576,500, and the highest PSTX revenue forecast at $3,393,517,750.
In 2027, PSTX is forecast to generate $7,418,229,802 in revenue, with the lowest revenue forecast at $7,418,229,802 and the highest revenue forecast at $7,418,229,802.